PHATHOM PHARMACEUTICALS, INC. (PHAT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD $1.19B; Treasury Stock, Common, ValueUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-1.53B.
- 2026-03-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $1.18B; Treasury Stock, Common, ValueUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-1.51B.
- 2025-12-31: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.05B; Treasury Stock, Common, ValueUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-1.48B.
- 2025-09-30: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.04B; Treasury Stock, Common, ValueUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-1.46B.
PHATHOM PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Common, Value USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.00K | $1.19B | $0.00 | $-1.53B | $-344.27M | 19.00 | 3 month · $6.71M | (m) |
| 2026-03-31 | $7.00K | $1.18B | $0.00 | $-1.51B | $-336.95M | 19.00 | 3 month · $5.53M | (m) |
| 2025-12-31 | $6.00K | $1.05B | $0.00 | $-1.48B | $-438.17M | 19.00 | 12 month · $28.72M | (m) |
| 2025-09-30 | $6.00K | $1.04B | $0.00 | $-1.46B | $-422.53M | 19.00 | 3 month · $9.30M | (m) |
| 2025-06-30 | $6.00K | $1.03B | $0.00 | $-1.43B | $-405.83M | 19.00 | 3 month · $8.27M | (m) |
| 2025-03-31 | $6.00K | $1.02B | $0.00 | $-1.36B | $-338.38M | 19.00 | 3 month · $5.54M | (m) |
| 2024-12-31 | $6.00K | $1.01B | $0.00 | $-1.26B | $-253.58M | 19.00 | 12 month · $24.05M | (m) |
| 2024-09-30 | $6.00K | $1.00B | $0.00 | $-1.19B | $-187.11M | 19.00 | 3 month · $5.63M | (m) |
| 2024-06-30 | $5.00K | $869.15M | $0.00 | $-1.10B | $-233.83M | 19.00 | 3 month · $6.10M | (m) |
| 2024-03-31 | $5.00K | $863.03M | $0.00 | $-1.01B | $-148.50M | 19.00 | 3 month · $5.63M | (m) |
| 2023-12-31 | $5.00K | $855.92M | $0.00 | $-928.68M | $-72.76M | 19.00 | 12 month · $45.02M | (m) |
| 2023-09-30 | $5.00K | $831.34M | $0.00 | $-849.12M | $-17.77M | 19.00 | 3 month · $6.14M | (m) |
| 2023-06-30 | $5.00K | $823.47M | $0.00 | $-805.87M | $17.60M | 19.00 | 3 month · $7.25M | (m) |
| 2023-03-31 | $4.00K | $674.71M | $0.00 | $-764.91M | $-90.19M | 19.00 | 3 month · $7.05M | (m) |
| 2022-12-31 | $3.00K | $652.28M | $0.00 | $-727.09M | $-74.81M | 19.00 | 12 month · $24.13M | (m) |
| 2022-09-30 | $3.00K | $645.62M | (m) | $-672.05M | $-26.42M | 19.00 | 3 month · $5.82M | (m) |
| 2022-06-30 | $3.00K | $613.95M | (m) | $-620.96M | $-7.00M | 19.00 | 3 month · $5.88M | (m) |
| 2022-03-31 | $3.00K | $608.07M | (m) | $-570.03M | $38.03M | 19.00 | 3 month · $5.78M | (m) |
| 2021-12-31 | $3.00K | $601.52M | (m) | $-529.37M | $72.16M | 1.00 | 12 month · $16.81M | 12 month · $1.29M |
| 2021-09-30 | $3.00K | $597.02M | (m) | $-493.54M | $103.48M | (m) | 3 month · $4.42M | 3 month · $1.29M |
| 2021-06-30 | $3.00K | $589.01M | (m) | $-456.88M | $132.13M | (m) | 3 month · $4.24M | (m) |
| 2021-03-31 | $3.00K | $584.67M | (m) | $-420.33M | $164.34M | (m) | 3 month · $3.82M | (m) |
| 2020-12-31 | $3.00K | $579.75M | (m) | $-385.49M | $194.27M | (m) | 12 month · $5.84M | (m) |
| 2020-09-30 | $3.00K | $488.15M | (m) | $-331.77M | $156.39M | (m) | 3 month · $2.07M | (m) |
| 2020-06-30 | $3.00K | $486.08M | (m) | $-297.66M | $188.42M | (m) | 3 month · $828.00K | (m) |
| 2020-03-31 | $2.00K | $485.25M | (m) | $-276.56M | $208.69M | (m) | 3 month · $563.00K | (m) |
| 2019-12-31 | $2.00K | $484.37M | (m) | $-256.42M | $227.96M | (m) | 12 month · $406.00K | (m) |
| 2019-09-30 | (m) | $5.95M | (m) | $-158.41M | $-152.46M | (m) | 3 month · $36.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | $-84.39M | (m) | 3 month · $29.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | $-2.54M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.00K | (m) | $-1.29M | $-1.29M | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $-802.00K | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-512.00K | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-252.00K | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |